• 1. Exclusive self-aligned β-phase PVDF films with abnormal piezoelectric coefficient prepared via phase inversion?
  N. Soin,D. Boyer,K. Prashanthi,S. Sharma,A. A. Narasimulu,J. Luo,T. H. Shah,E. Siores,T. Thundat Chem. Commun., 2015,51, 8257-8260
• 2. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 3. Enantio- & chemo-selective preparation of enantiomerically enriched aliphatic nitro alcohols using Candida parapsilosis ATCC 7330
  Sowmyalakshmi Venkataraman RSC Adv., 2015,5, 73807-73813
• 4. Estimates of hydride ion stability in condensed systems: energy of formation and solvation in aqueous and polar-organic solvents
  Craig A. Kelly,David R. Rosseinsky Phys. Chem. Chem. Phys., 2001,3, 2086-2090
• 5. Estimation of fusel-oil in spirits
  Analyst, 1890,15, 203-209

Introduction to (2,6-Dibromophenyl)methanamine and Its Applications in Modern Chemical Research

The compound with the CAS number 1214323-07-5 is known as (2,6-dibromophenyl)methanamine, a molecule that has garnered significant attention in the field of chemical biology and pharmaceutical research. This compound, characterized by its unique structural features, has found utility in various applications, particularly in the development of novel therapeutic agents and the exploration of biochemical pathways.

At the heart of its significance lies the presence of two bromine atoms at the 2 and 6 positions of the phenyl ring, which enhances its reactivity and makes it a valuable intermediate in synthetic chemistry. The amine functional group at the methylene bridge provides a site for further functionalization, allowing chemists to tailor its properties for specific applications. This combination of structural elements has made (2,6-dibromophenyl)methanamine a versatile building block in the synthesis of more complex molecules.

In recent years, there has been a growing interest in exploring the potential of halogenated aromatic compounds in drug discovery. The bromine atoms in (2,6-dibromophenyl)methanamine not only increase its lipophilicity but also serve as handles for cross-coupling reactions, which are fundamental to modern organic synthesis. These reactions are pivotal in constructing intricate molecular architectures that mimic natural products and bioactive compounds.

One of the most promising areas where (2,6-dibromophenyl)methanamine is being utilized is in the development of kinase inhibitors. Kinases are enzymes that play a crucial role in cell signaling pathways and are often implicated in diseases such as cancer. By designing molecules that can selectively inhibit specific kinases, researchers aim to develop targeted therapies with improved efficacy and reduced side effects. The brominated phenyl ring in (2,6-dibromophenyl)methanamine provides a scaffold that can be modified to interact with the active site of kinases, making it an attractive candidate for this purpose.

Moreover, the compound has shown promise in the field of materials science. Its ability to undergo various chemical transformations allows for the creation of novel polymers and coatings with enhanced properties. For instance, researchers have explored its use in synthesizing conductive polymers that could be employed in electronic devices. The bromine atoms facilitate polymerization reactions, leading to materials with tailored electrical and thermal characteristics.

The synthesis of (2,6-dibromophenyl)methanamine itself is an intriguing process that highlights the ingenuity of organic chemists. Traditional methods involve bromination of aniline derivatives followed by methylation, but recent advances have led to more efficient and sustainable routes. For example, catalytic bromination techniques have been developed that minimize waste and improve yields. These innovations align with the growing emphasis on green chemistry principles in industrial applications.

In academic research, (2,6-dibromophenyl)methanamine has been used as a substrate to study reaction mechanisms and develop new catalytic systems. Its unique reactivity profile allows researchers to probe fundamental questions about electron transfer processes and molecular rearrangements. Such studies not only contribute to our fundamental understanding of chemistry but also lay the groundwork for developing new synthetic methodologies.

The pharmaceutical industry has also embraced the potential of (2,6-dibromophenyl)methanamine as a key intermediate in drug development. Its structural features make it amenable to modifications that can enhance drug-like properties such as solubility, bioavailability, and metabolic stability. By leveraging computational tools and high-throughput screening techniques, researchers can rapidly identify derivatives with improved pharmacological profiles.

Looking ahead, the future prospects for (2,6-dibromophenyl)methanamine appear promising. As our understanding of biological systems grows, so does the demand for sophisticated chemical tools to study them. This compound is well-positioned to play a critical role in this endeavor by serving as a versatile scaffold for innovation. Whether it is through the development of new drugs or advanced materials, its contributions are likely to be far-reaching.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)